熱門資訊> 正文
CONMED因Airseal一次性购买数据和关税而在Stifel降级
2025-04-29 00:53
- Stifel has downgraded CONMED (NYSE:CNMD) to hold from buy citing Q1 hospital purchasing data on Airseal disposables as a key factor.
- The investment bank also cut its price target to $55 from $75 (~8% upside based on April 25 close).
- Analyst Rick Wise noted that the data indicates the quarter was the first time Airseal sales declined year over year since 2020.
- He added that uncertainty over tariffs and the economy are weighing on CONMED, as well as "the company's back-end weighted 2025 guidance."
- "Thus, until we get a clearer sense that the macro issues are
going to be less of a concern and that the insufflation data is going to turn more positive, we feel compelled to move to the sidelines as we await greater clarity on the company’s strategic operational, and Airseal-offsetting priorities," Wise wrote.
More on CONMED
- Repeated Disappointments On Growth And Margins Leaves Conmed Even Deeper In The Doghouse
- CONMED Corporation (CNMD) Q4 2024 Earnings Call Transcript
- Conmed cut to Neutral at J.P. Morgan after guidance miss
- Conmed anticipates $1.344B–$1.372B revenue in 2025 with focus on operational improvements
- Seeking Alpha’s Quant Rating on CONMED
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
